Free Trial
NASDAQ:XERS

Xeris Biopharma (XERS) Stock Price, News & Analysis

Xeris Biopharma logo
$5.14 -0.13 (-2.37%)
As of 11:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Xeris Biopharma Stock (NASDAQ:XERS)

Key Stats

Today's Range
$5.11
$5.28
50-Day Range
$4.30
$5.34
52-Week Range
$2.10
$6.07
Volume
421,489 shs
Average Volume
2.05 million shs
Market Capitalization
$804.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.25
Consensus Rating
Moderate Buy

Company Overview

Xeris Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

XERS MarketRank™: 

Xeris Biopharma scored higher than 63% of companies evaluated by MarketBeat, and ranked 376th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Xeris Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Xeris Biopharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Xeris Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Xeris Biopharma are expected to grow in the coming year, from ($0.41) to ($0.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Xeris Biopharma is -17.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Xeris Biopharma is -17.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Xeris Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    12.27% of the float of Xeris Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Xeris Biopharma has a short interest ratio ("days to cover") of 6.9.
  • Change versus previous month

    Short interest in Xeris Biopharma has recently increased by 1.93%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Xeris Biopharma does not currently pay a dividend.

  • Dividend Growth

    Xeris Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.27% of the float of Xeris Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Xeris Biopharma has a short interest ratio ("days to cover") of 6.9.
  • Change versus previous month

    Short interest in Xeris Biopharma has recently increased by 1.93%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Xeris Biopharma this week, compared to 2 articles on an average week.
  • Search Interest

    14 people have searched for XERS on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Xeris Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $109,500.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 6.47% of the stock of Xeris Biopharma is held by insiders.

  • Percentage Held by Institutions

    42.75% of the stock of Xeris Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Xeris Biopharma's insider trading history.
Receive XERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter.

XERS Stock News Headlines

Xeris Biopharma Holdings, Inc. (XERS) - Yahoo Finance
[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
Xeris Announces Details for Analyst & Investor Day
See More Headlines

XERS Stock Analysis - Frequently Asked Questions

Xeris Biopharma's stock was trading at $3.39 at the start of the year. Since then, XERS shares have increased by 55.5% and is now trading at $5.27.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) released its earnings results on Thursday, May, 8th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. The business earned $57.80 million during the quarter, compared to analyst estimates of $57.61 million.
Read the conference call transcript
.

Xeris Biopharma (XERS) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Mizuho Securities was co-manager.

Xeris Biopharma's top institutional investors include Wealth Enhancement Advisory Services LLC (0.02%) and Pallas Capital Advisors LLC (0.01%). Insiders that own company stock include Paul R Edick, Kevin Mcculloch, John Patrick Shannon Jr and Beth Hecht.
View institutional ownership trends
.

Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Xeris Biopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), CymaBay Therapeutics (CBAY) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
5/08/2025
Today
7/11/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:XERS
CIK
1867096
Fax
N/A
Employees
290
Year Founded
N/A

Price Target and Rating

High Price Target
$8.00
Low Price Target
$4.00
Potential Upside/Downside
+21.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$54.84 million
Net Margins
-20.25%
Pretax Margin
-21.41%
Return on Equity
N/A
Return on Assets
-12.07%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.72
Quick Ratio
1.17

Sales & Book Value

Annual Sales
$203.07 million
Price / Sales
3.95
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.20) per share
Price / Book
-25.68

Miscellaneous

Outstanding Shares
156,380,000
Free Float
146,267,000
Market Cap
$803.01 million
Optionable
Optionable
Beta
0.66

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:XERS) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners